D017472Chemicals & DrugsD12.776.543.750.705.852.420.300560.998085Receptors, Interleukin-1Faculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson31068441Li T, Chubinskaya S, Esposito A, Jin X, Tagliafierro L, Loeser R, Hakimiyan AA, Longobardi L, Ozkan H, Spagnoli AScience translational medicineTGF-? type 2 receptor-mediated modulation of the IL-36 family can be therapeutically targeted in osteoarthritis. Sci Transl Med. 2019 05 08; 11(491).Sci Transl Med2019-05-08T00:00:002019TGF-? type 2 receptor-mediated modulation of the IL-36 family can be therapeutically targeted in osteoarthritis.8849376Drevlow BE, Lovis R, Haag MA, Sinacore JM, Jacobs C, Blosche C, Landay A, Moreland LW, Pope RMArthritis and rheumatismRecombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. 1996 Feb; 39(2):257-65.Arthritis Rheum1996-02-01T00:00:001996Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis.true1ProfessorProfessorHowardAnHoward An41.87352120000000-87.66713820000000349055An, HowardProfessortrue1ProfessorProfessorPediatricsAnnaSpagnoliAnna Spagnoli41.87386750000000-87.67102690000000349109Spagnoli, AnnaProfessorRobertBalkRobert A. Balk349167Balk, RobertProfessor5Associate Professor4ProfessorOrthopedic SurgeryRush University, Rush Medical CollegeAlanLandayAlan L. Landay41.87386750000000-87.67102690000000349009Landay, AlanProfessorVineetGuptaVineet Gupta41.87386750000000-87.67102690000000349018Gupta, VineetAssociate Professor0.1777910.03544935research area of0.2389140.04412087subject area for9233735Opal SM, Fisher CJ, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff MCritical care medicineConfirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med. 1997 Jul; 25(7):1115-24.Crit Care Med1997-07-01T00:00:001997Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.true1Associate ProfessorAssociate Professortrue1ProfessorProfessorInternal Medicine, Division of Geriatrics, Gerontology and Palliative MedicineInternal Medicine, Division of NephrologyInternal Medicine, Division of Pulmonary Disease Critical Care28970361Nomura A, Gupta VK, Dauer P, Sharma NS, Dudeja V, Merchant N, Saluja AK, Banerjee SMolecular cancer research : MCRNF?B-Mediated Invasiveness in CD133+ Pancreatic TICs Is Regulated by Autocrine and Paracrine Activation of IL1 Signaling. Mol Cancer Res. 2018 01; 16(1):162-172.Mol Cancer Res2017-09-28T00:00:002017NF?B-Mediated Invasiveness in CD133+ Pancreatic TICs Is Regulated by Autocrine and Paracrine Activation of IL1 Signaling.37569715Kakutani K, Yurube T, An HS, Doita M, Masuda KInternational journal of molecular sciencesCytokine Inhibitors Upregulate Extracellular Matrix Anabolism of Human Intervertebral Discs under Alginate Beads and Alginate-Embedded Explant Cultures. Int J Mol Sci. 2023 Aug 02; 24(15).Int J Mol Sci2023-08-02T00:00:002023Cytokine Inhibitors Upregulate Extracellular Matrix Anabolism of Human Intervertebral Discs under Alginate Beads and Alginate-Embedded Explant Cultures.true1ProfessorProfessor